Evolvence India Life Sciences Fund
Evolvence India Life Sciences Fund is a Mauritius-based Private Equity fund established in 2006 to provide growth capital to companies operating in the Indian healthcare sector. EILSF is sponsored by Evolvence Capital. In addition, its investors include leading institutional investors, family offices, pension funds, and sovereign wealth funds from Europe and GCC region.
EILSF invests in small to mid-sized pharmaceutical, biopharmaceutical, medical device, contract R&D, and healthcare services businesses which are either located in India or which derive significant competitive advantage from operations located in India. Examples of investments include providing capital for capacity expansion; development of generic versions of drugs facing patent expiry; domestic and international acquisitions; and up-gradation of existing infrastructure to emerge as ‘partner of choice’ for contract R&D and manufacturing activities.
EILSF’s team of investment professionals has deep understanding of the global life sciences sector, operational experience, and a privileged network of contacts in India and other major international markets. The overarching investment strategy of the Fund was developed after a thorough analysis of the Indian pharma and healthcare sectors and key global macro trends. Deal flow is generated primarily by leveraging the team’s strong on-the-ground network. Investment opportunities that fit with the stated strategy are then carefully vetted by drawing on the team’s domain insights. After a rigorous business, financial, legal and regulatory diligence process, investments are deliberated upon by an Investment Committee following which they are approved by the Fund Board.
Post-investment, the EILSF team partners with management teams of the portfolio companies helping them recognize and capture untapped value in the business they are in. The team provides strategic guidance based on proprietary market insight, helps identify opportunities for improving business processes and achieving operational excellence, and assists companies in business development activities overseas.
For more info: email@example.com >
"Emerging markets will contribute 40-50% of total global growth of the pharmaceutical industry in the next five years"